Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone vs oxycodone sustained-release plus denosumab for cancer bone metastasis pain
ChiCTR2500108939Phase 4Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in cancer pain and bone metastases comparing Hydromorphone + denosumab with Oxycodone + denosumab (2 arms). Primary endpoints: Adverse reaction incidence rate and Pain relief rate after 8 weeks of treatment. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
hydromorphoneoxycodonedenosumab
03
Conditions
cancer painbone metastases
Beyond the preview
Go deeper on ChiCTR2500108939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108939.